Therapeutic effect and safety of large dosage of valsartan on chronic heart failure
10.3969/j.issn.1008-0074.2014.04.25
- VernacularTitle:大剂量缬沙坦治疗慢性心力衰竭的疗效和安全性
- Author:
Jin ZHANG
;
Xuansheng HUANG
- Publication Type:Journal Article
- Keywords:
Heart failure,congestive;
Treatment outcome;
Valsartan
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2014;23(4):449-452
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical therapeutic effect and safety of large dosage of valsartan on chronic heart failure (CHF).Methods:A total of 106 CHF patients hospitalized in our department were chosen and ran-domly divided into routine dose group (n=53,received routine dosage of valsartan,80mg,once/d)and large dose group (n=53,received large dosage of valsartan,80mg,twice/d)accerding to number table.Both groups received anti-heart failure treatment for six months according to the guidelines.After treatment,plasma N terminal pro brain natriuretic peptide (NT-proBNP)level was measured,left ventricular end-systolic diameter (LVESd),left ventricu-lar end-diastolic diameter (LVEDd),interventricular septal thickness (IVST)and left ventricular posterior wall thickness (LVPWT)were measured by color Doppler echocardiography,and all patients received 6min walking test. Therapeutic effect and incidence rates of adverse reactions were compared and analyzed between two groups after treatment.Results: Compared with routine dose group,there were significant reductions in NT-proBNP level [(3042.6±116.3)pmol/L vs.(2565.8±98.2)pmol/L],LVESd [(34.5±2.2)mm vs.(29.4± 2.0)mm], LVEDd [(55.1±2.9)mm vs.(50.2±2.5)mm],IVST [(12.9±1.8)mm vs.(10.7±1.2)mm]and LVPWT [(11.8±1.1)mm vs.(10.9±0.9)mm];significant rise in 6min walking distance [(271.2±24.9)m vs.(367.7 ±22.3)m]and total effective rate (43.40% vs.62.26%)in large dose group,P <0.05 all.There was no signifi-cant difference in incidence rates of major adverse reactions between two groups (P >0.05).Conclusion:Large dos-age of valsartan is more effective and is safe in treatment of chronic heart failure.
